PARP1 and cancer: Replication fork remodelers such as SMARCAL1, ZRANB3, and HLTF can partially counteract this vulnerability by promoting fork reversal, recruiting protective factors, stabilizing forks, preventing excessive DNA damage accumulation, and allowing cancer cell survival despite PARP inhibitor treatment.